Profile data is unavailable for this security.
About the company
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing ONS-5010 (LYTENAVA (bevacizumab-vikg)), an ophthalmic formulation of bevacizumab for use in retinal indications. The Company's product candidate, ONS-5010, is developed to be administered as an intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab is a full-length, humanized anti-Vascular Endothelial Growth Factor (VEGF) recombinant monoclonal antibody (mAb), that inhibits VEGF and associated angiogenic activity. VEGF is a protein that promotes the growth of new abnormal blood vessels. Its biologics license application (BLA) for ONS-5010 in wet AMD involved three clinical trials, which include NORSE ONE, NORSE TWO and NORSE THREE. The Company sells ONS-5010 in the United States, United Kingdom, Europe, Japan and other markets.
- Revenue in USD (TTM)0.00
- Net income in USD-159.13m
- Incorporated2015
- Employees24.00
- LocationOutlook Therapeutics Inc111 S. Wood Avenue, Unit #100ISELIN 08830United StatesUSA
- Phone+1 (609) 619-3990
- Websitehttps://outlooktherapeutics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Achieve Life Sciences Inc | 0.00 | -27.32m | 168.27m | 22.00 | -- | 3.39 | -- | -- | -1.29 | -1.29 | 0.00 | 1.44 | 0.00 | -- | -- | 0.00 | -60.15 | -86.31 | -109.37 | -119.59 | -- | -- | -- | -- | -- | -9.33 | 0.2574 | -- | -- | -- | 29.60 | -- | -14.51 | -- |
X4 Pharmaceuticals Inc | 0.00 | -128.91m | 171.30m | 93.00 | -- | 165.34 | -- | -- | -0.6968 | -0.6968 | 0.00 | 0.0062 | 0.00 | -- | -- | 0.00 | -108.98 | -61.53 | -133.20 | -69.20 | -- | -- | -- | -13,288.93 | -- | -- | 0.9815 | -- | -- | -- | -4.93 | -- | 12.03 | -- |
Elite Pharmaceuticals Inc | 47.32m | 15.55m | 171.35m | 53.00 | 11.03 | 3.69 | 10.13 | 3.62 | 0.0153 | 0.0153 | 0.0465 | 0.0456 | 0.7428 | 2.24 | 4.39 | 892,785.50 | 24.41 | 3.53 | 30.62 | 4.61 | 45.82 | 46.10 | 32.87 | 4.41 | 1.19 | 1.18 | 0.1449 | 0.00 | 5.87 | 35.57 | -59.97 | -- | 83.62 | -- |
Lineage Cell Therapeutics Inc | 8.00m | -23.66m | 173.60m | 75.00 | -- | 2.40 | -- | 21.69 | -0.1344 | -0.1344 | 0.0455 | 0.3836 | 0.0722 | -- | 57.16 | 106,706.70 | -21.32 | -19.53 | -24.82 | -22.59 | 91.88 | 89.13 | -295.30 | -370.88 | -- | -- | 0.0018 | -- | -39.16 | 12.39 | 18.22 | -- | -27.16 | -- |
Elevation Oncology Inc | 0.00 | -39.35m | 176.48m | 29.00 | -- | 2.20 | -- | -- | -1.03 | -1.03 | 0.00 | 1.47 | 0.00 | -- | -- | 0.00 | -42.35 | -- | -46.30 | -- | -- | -- | -- | -- | -- | -12.50 | 0.2889 | -- | -- | -- | 51.93 | -- | -- | -- |
Outlook Therapeutics Inc | 0.00 | -159.13m | 179.52m | 24.00 | -- | -- | -- | -- | -11.48 | -11.48 | 0.00 | -6.10 | 0.00 | -- | -- | 0.00 | -281.52 | -214.69 | -2,060.72 | -1,843.48 | -- | -- | -- | -3,043.92 | -- | -26.75 | -- | -- | -- | -- | 10.70 | -- | -- | -- |
Generation Bio Co | 9.96m | -169.06m | 182.29m | 174.00 | -- | 1.38 | -- | 18.30 | -2.56 | -2.56 | 0.1509 | 1.99 | 0.0278 | -- | 10.98 | 57,258.62 | -47.14 | -36.96 | -50.75 | -39.21 | -- | -- | -1,696.87 | -8,879.44 | -- | -- | 0.00 | -- | -- | 177.31 | 7.34 | -- | 19.61 | -- |
bluebird bio Inc | 21.73m | -91.17m | 182.67m | 323.00 | -- | 0.4615 | -- | 8.41 | -0.7446 | -0.7446 | 0.2139 | 2.08 | 0.0383 | -- | -- | 67,263.16 | -16.08 | -33.02 | -21.50 | -37.14 | -10.08 | 19.44 | -419.62 | -4,044.31 | 1.42 | -- | 0.00 | -- | -1.77 | -36.71 | 52.62 | -- | -26.66 | -- |
Fennec Pharmaceuticals Inc | 44.95m | 2.84m | 184.70m | 36.00 | 184.85 | 60.79 | 64.94 | 4.11 | 0.0366 | 0.0366 | 1.62 | 0.1112 | 0.9878 | 1.15 | 7.52 | -- | 6.25 | -73.43 | 7.37 | -84.32 | 96.19 | -- | 6.33 | -383.28 | 6.72 | 1.84 | 0.9087 | -- | 1,284.50 | -- | 32.34 | -- | -- | -- |
XBiotech Inc | 0.00 | -30.74m | 185.79m | 92.00 | -- | 0.8876 | -- | -- | -1.01 | -1.01 | 0.00 | 6.87 | 0.00 | -- | -- | 0.00 | -13.08 | 31.88 | -13.68 | 33.27 | -- | -- | -- | 877.30 | -- | -- | 0.0456 | 0.00 | -100.00 | -- | 25.36 | -- | 24.30 | -- |
Trevi Therapeutics Inc | 0.00 | -33.57m | 186.65m | 25.00 | -- | 2.53 | -- | -- | -0.338 | -0.338 | 0.00 | 1.05 | 0.00 | -- | -- | 0.00 | -34.47 | -47.39 | -38.08 | -54.41 | -- | -- | -- | -- | -- | -- | 0.0017 | -- | -- | -- | 0.2984 | -- | -2.81 | -- |
Abeona Therapeutics Inc | 3.50m | -76.66m | 188.22m | 84.00 | -- | -- | -- | 53.78 | -3.20 | -3.20 | 0.1461 | -0.3224 | 0.0546 | -- | 2.54 | 41,666.67 | -119.62 | -53.22 | -140.83 | -65.81 | -- | -- | -2,190.26 | -1,894.25 | -- | -- | 1.97 | -- | 147.52 | 3.14 | -24.63 | -- | -55.74 | -- |
Invivyd Inc | 0.00 | -206.82m | 188.52m | 94.00 | -- | 1.06 | -- | -- | -1.86 | -1.86 | 0.00 | 1.50 | 0.00 | -- | -- | 0.00 | -73.08 | -- | -81.48 | -- | -- | -- | -- | -- | 5.77 | -- | 0.00 | -- | -- | -- | 17.68 | -- | -- | -- |
Greenwich Lifesciences Inc | 0.00 | -9.24m | 190.11m | 3.00 | -- | 37.11 | -- | -- | -0.719 | -0.719 | 0.00 | 0.3977 | 0.00 | -- | -- | 0.00 | -106.03 | -36.43 | -109.97 | -38.31 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.63 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Tang Capital Management LLCas of 31 Mar 2024 | 1.62m | 6.92% |
Great Point Partners LLCas of 01 Apr 2024 | 1.48m | 6.32% |
Armistice Capital LLCas of 31 Mar 2024 | 714.29k | 3.05% |
Sphera Funds Management Ltd.as of 31 Mar 2024 | 571.43k | 2.44% |
Caligan Partners LPas of 31 Mar 2024 | 500.00k | 2.14% |
Velan Capital Investment Management LPas of 31 Mar 2024 | 500.00k | 2.14% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 467.12k | 2.00% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 326.45k | 1.40% |
Rosalind Advisors, Inc.as of 31 Mar 2024 | 311.78k | 1.33% |
Schonfeld Strategic Advisors LLCas of 31 Mar 2024 | 285.71k | 1.22% |